A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma.

This document provides administrative information about a clinical trial conducted in China for the treatment of relapsed or refractory large B-cell lymphoma. The trial is being conducted by Shanghai Ming Ju Biotechnology Co., Ltd. and involves adult patients who have already been treated with Relmacabtagene Autoleucel. The trial is expected to be completed by December 2024. The document also includes contact information for the primary investigator and collaborating hospitals. [Extracted from the article]